锦波生物(832982) - 2023 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders in the range of 28,000 to 30,000 thousand yuan, representing an increase of 156.47% to 174.79% compared to the same period last year, which was 10,917.50 thousand yuan[4]. - The significant increase in performance is attributed to the company's continuous investment in research and development, active development of new products and product upgrades, as well as enhanced brand promotion and market expansion efforts[5]. - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by an accounting firm, thus it does not constitute a commitment to investors regarding performance[6].